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ABSTRACT
Objective: Isatins have emerged as antimicrobial agents due to their broad spectrum of in vitro and in vivo antimicrobial activities. In addition, 
thiazolidinone also reported to possess various biological activities particularly antimicrobial activity. Due to the importance, we planned to 
synthesize compounds with isatin functionality coupled with thiazolidinone as possible antitubercular and antimicrobial agents which could furnish 
better therapeutic results.
Methods: In vitro Mycobacterium tuberculosis method and agar streak dilution test are used to estimate antitubercular and antimicrobial potency 
of title analogs, respectively. Minimum inhibitory concentration of entire title compounds was determined against all tested microorganism such as 
M. tuberculosis, four Gram-positive, three Gram-negative bacteria, and two fungi.
Results: A series of new thiazolidinone substituted Schiff and Mannich bases of 5-nitroisatins were designed and synthesized by a multistep synthesis 
from isatin. Structures of synthesized compounds are characterized using Fourier-transform infrared, proton nuclear magnetic resonance, mass 
spectroscopy, and bases of elemental analysis. Mild to good antitubercular and antimicrobial activity was showed by synthesized 5-nitroisatin analogs. 
The relationship between the biological activity and the functional group variation of the tested compounds was discussed.
Conclusion: 3-(4-(3-(4-Aminophenyl)-4-oxothiazolidin-2-yl)phenylimino)-1-((dimethyl amino)methyl)-5-nitroindolin-2-one 6 and 3-(4-(3- 
(2-aminophenyl)-4-oxothiazolidin-2-yl)phenylimino)-1-((dimethylamino)methyl)-5-nitroindolin-2-one 13 were found to be the most potent 
compounds of this series which might be extended as a novel class of antimicrobial agents.
Keywords: 5-Nitroisatin, Indole-2,3-dione, Schiff base, Mannich base, Antitubercular activity, Antimicrobial activity.
INTRODUCTION
Bacteria Mycobacterium tuberculosis is the causative organism for 
tuberculosis (TB). In general, a lung is a major part affected by TB, but 
other parts can also be affected by TB. Globally within diseases caused 
by single infectious agent TB is the second largest killer. According to 
the WHO, every year about 9 million people are affected by TB. Among 
them, 3 million people are missed by current health systems. TB is 
one of the top three reasons for the death of women aged between 15 
and 44. TB is an airborne disease and is two types, i.e., latent TB and 
active TB [1]. Chronic cough with sputum containing blood, weight loss, 
fever, and night sweats is the characteristic symptoms of active TB. It 
is believed that about one-third of the world’s population has latent 
TB. Latent TB becoming active only in 10% cases, but the risk is much 
higher in people who have compromised immune systems, i.e., people 
living with HIV or malnutrition, or people who smoke [2].
Serious life-threatening adverse effect of available antitubercular 
drugs (anorexia, asthenia, depression, neuritis, hepatotoxicity, etc.) and 
development of resistance are the two common problems associated 
with TB treatment [3,4]. In addition, around the world, the emergence 
and increase of multidrug-resistant (MDR) and extensively drug resistant 
(XDR) strains of M. tuberculosis have been alarming authorities. High 
mortality rates and low cure rates are the two major difficulties faced 
in the treatment due to these strains [5,6]. Furthermore, in the clinic, 
drug-resistant TB cases are also reported [7,8]. Hence, a priority task 
is the development of new drugs with activity against MDR-TB, XDR-TB, 
and XDR-TB. Moreover, new agents that will shorten the duration of 
current chemotherapy are also needed. To tackle the menace, there is a 
need to search for newer therapeutic agents [9].
Majority of the currently available medicinal compounds consist of one 
or more heterocyclic ring system. From the contemporary medicinal 
chemistry investigation, it was found that isatin is one such significant 
heterocyclic system which has been gained magnitude due to the broad 
array of biological activities [10-18]. Isatins have emerged as antimicrobial 
agents due to their broad spectrum of in vitro and in vivo antimicrobial 
activities [19-27]. In addition, thiazolidinone also reported to possess 
various biological activities particularly antimicrobial activity [28-32]. 
Due to the importance, we planned to synthesize compounds with isatin 
functionality coupled with thiazolidinone as possible antitubercular 
and antimicrobial agents which could furnish better therapeutic 
results. Based on these findings, with the hope to obtain more active 
and less toxic antimicrobial agents, we decided to synthesize a new 
series of 1-((dimethylamino)methyl)-3-(4-(3-(substitutedphenyl)-4-
oxothiazolidin-2-yl)phenyl imino)-5-nitroindolin-2-ones and evaluated 
its antitubercular and antimicrobial activities.
MATERIALS AND METHODS
Materials
The chemicals and reagents used were obtained from various chemical 
units Qualigens, E. Merck India Ltd., CDH, and SD Fine Chem. These 
solvents used were of LR grade and purified before their use. The silica 
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gel G used for analytical chromatography (tthin-layer chromatography 
[TLC]) was obtained from E. Merck India Ltd. All the melting points 
were taken in open glass capillary and are uncorrected. Proton nuclear 
magnetic resonance ( 1H-NMR) spectra were recorded at 500 MHz on 
Bruker Avance-500 NMR spectrometer in CDCl3 using tetramethylsilane 
as an internal standard. The chemical shifts are reported in ppm scale. 
Mass spectra were obtained on a JEOL-SX-102 instrument using electron 
impact ionization. All the IR spectra were recorded in KBr pellets on a 
Jasco Fourier-transform infrared (FT-IR) 410 spectrometer. Elemental 
analyses were performed on a Perkin Elmer model 2400C analyzer and 
were within ±0.4% of the theoretical values.
Preparation of 5-nitroisatin (2)
According to the reported literature, the 5-nitroisatin 2 was 
prepared [33]. In 500 ml round-bottomed flask (RBF), 0.33 mol of 
isatin (48.5 g) was added slowly to a mixture of 0.5 mol conc. nitric acid 
(35 ml/50 g) and 0.75 mol conc. sulfuric acid (40 ml/74 g) with frequent 
shaking. In crushed ice cold water, the flask was immersed and cooled. 
After adding all isatin, at 60°C, the contents of the RBF were refluxed 
in water for the period of 1 h. Later in a beaker containing 500 ml cold 
water, the refluxed mixture was transferred and stirred to remove 
excess acid present. At the bottom, 5-nitroisatin 2 was settled down 
completely and the acidic upper layer was removed by decantation. 
Then in separating funnel, the residual bottom layer was transferred, 
50 ml of water was added to it and shaken vigorously. Finally, to obtain 
pure 5-nitroisatin 2 the residual layer was collected, filtered, and dried 
with anhydrous calcium chloride. Yield = 68%, m.p. 230–232°C. IR 
(KBr) cm−1: 3349 (NH), 3025 (Ar-CH), 1731 (C=O), 1613 (C=C), 1546 
and 1328 (NO2). 1H-NMR (CDCl3, 500 MHz) δ ppm: 7.19–7.62 (m, 3H, 
Ar-CH), 9.16 (s, 1H, NH of isatin). EI-MS m/z: 192 (M+). Anal. Calcd for 
C8H4N2O4: C, 50.01; H, 2.10; N, 14.58. Found: C, 50.19; H, 2.09; N, 14.53.
Preparation of 4-(5-nitro-2-oxoindolin-3-ylideneamino)
benzaldehyde (3)
0.1 Mol of 5-nitro isatin 2 (19.2 g) and 0.1 mol of p-amino benzaldehyde 
(12.1 g) were dissolved in warm ethanol (150 ml) containing catalytic 
quantities of glacial acetic acid (5 ml). At 100°C, the contents were refluxed 
in a water bath for the period of 4 h and set aside for 1 h. The resultant 
product 4-(5-nitro-2-oxoindolin-3-ylideneamino)benzaldehyde three 
was collected, filtered, washed with ethanol, and dried. Yield = 74%, 
m.p. 197–199°C. IR (KBr) cm−1: 3371 (NH), 3018 (Ar-CH), 1720 (C=O), 
1669 (C=N), 1604 (C=C), 1522 and 1335 (NO2). 1H-NMR (CDCl3, 500 MHz) 
δ ppm: 7.25–7.91 (m, 7H, Ar-CH), 9.27 (s, 1H, NH of isatin), 10.13 (s, 1H, 
CH of CHO). EI-MS m/z: 295 (M+). Anal. Calcd for C15H9N3O4: C, 61.02; H, 
3.07; N, 14.23. Found: C, 60.87; H, 3.08; N, 14.27.
Preparation of 4-(1-((dimethylamino)methyl)-5-nitro-2-
oxoindolin-3-ylideneamino) benzaldehyde (4)
To the solution of 0.05 mol 4-(5-nitro-2-oxoindolin-3-ylideneamino)
benzaldehyde 3 (14.75 g) in ethanol (100 ml), 37% aqueous 
formaldehyde (1.5 ml) was added. Then, 0.05 mol of dimethylamine 
(2.25 g) was added with stirring slowly to the above mixture. The 
entire reaction mixture was stirred after adding all dimethylamine for 
5 h mechanically at room temperature and kept in the refrigerator for 
1 day to form crystals. The obtained crystals of 4-(1-((dimethylamino)
methyl)-5-nitro-2-oxoindolin-3-ylideneamino)benzaldehyde 4 were 
separated by filtration and dried in vacuum. To obtain pure product 
compound 4 was recrystallized using ethanol. Yield = 72 m.p. 214–
217°C. IR (KBr) cm−1: 3009 (Ar-CH), 2884 (CH3-CH), 1715 (C=O), 1642 
(C=N), 1628 (C=C), 1541 and 1340 (NO2). 1H-NMR (CDCl3, 500 MHz) δ 
ppm: 2.17 (s, 6H, N(CH3)2), 4.32 (s, 2H, CH2 linkage), 7.04–7.85 (m, 7H, 
Ar-CH), 10.22 (s, 1H, CH of CHO). EI-MS m/z: 352 (M+). Anal. Calcd for 
C18H16N4O4: C, 61.36; H, 4.58; N, 15.90. Found: C, 61.49; H, 4.60; N, 15.85.
General procedure for synthesis of 1-((dimethylamino)methyl)-3-
(4-(3-(substituted phenyl)-4-oxothiazolidin-2-yl)phenylimino)-5-
nitroindolin-2-one (5-19)
To a mixture of 0.01 mol 4-(1-((dimethylamino)methyl)-5-nitro-
2-oxoindolin-3-ylideneamino)benzaldehyde 4 (3.52 g) and 0.01 
mol various aryl amines in ethanol (20 ml) 0.01 mol mecaptoacetic 
acid (0.92 g) were added with stirring slowly. Latter a mixture of 
zinc chloride (0.5 g) in ethanol (10 ml) was added with vigorous 
stirring slowly. The contents were refluxed in a water bath at 
100°C for 12 h. Then, the reaction mixture was poured into ice cold 
water and stirred well. The product separated 5–19 were filtered, 
washed with water and dried. The residue was recrystallized from 
ethanol.
1 - ( ( D i m e t h y l a m i n o ) m e t h y l ) - 5 - n i t r o - 3 - ( 4 - ( 4 - o x o - 3 -
phenylthiazolidin-2-yl)phenylimino) indolin-2-one (5)
Yield = 75%, m.p. 274–276°C. IR (KBr) cm−1: 3002 (Ar-CH), 2937 
(CH2-CH), 1715 (C=O), 1650 (C=N), 1623 (C=C), 1536 and 1348 (NO2). 
1H-NMR (CDCl3, 500 MHz) δ ppm: 2.26 (s, 6H, N(CH3)2), 3.64 (s, 2H, 
CH2 of thiazolidinone), 4.18 (s, 2H, CH2 linkage), 6.07 (s, 1H, CH of 
thiazolidinone), 6.93–7.88 (m, 12H, Ar-CH). EI-MS m/z: 501 (M+). Anal. 




Yield = 78%, m.p. 208–210°C. IR (KBr) cm−1: 3364 (NH), 3029 (Ar-CH), 
2950 (CH2-CH), 1737 (C=O), 1673 (C=N), 1621 (C=C), 1548 and 1312 
(NO2).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.32 (s, 6H, N(CH3)2), 3.56 (s, 
2H, CH2 of thiazolidinone), 4.24 (s, 2H, NH2), 4.31 (s, 2H, CH2 linkage), 
6.25 (s, 1H, CH of thiazolidinone), 7.18-8.03 (m, 11H, Ar-CH). EI-MS 
m/z: 516 (M+). Anal. Calcd. for C26H24N6O4S: C, 60.45; H, 4.68; N, 16.27. 
Found: C, 60.62; H, 4.66; N, 16.23.
1-((Dimethylamino)methyl)-3-(4-(3-(4-hydroxyphenyl)-4-
oxothiazolidin-2-yl)phenyl imino)-5-nitroindolin-2-one (7)
Yield = 79%, m.p. 291–294°C. IR (KBr) cm−1: 3652 (OH), 3016 (Ar-CH), 
2941 (CH2-CH), 1734 (C=O), 1663 (C=N), 1618 (C=C), 1529 and 1325 
(NO2).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.41 (s, 6H, N(CH3)2), 3.47 (s, 
2H, CH2 of thiazolidinone), 4.29 (s, 2H, CH2 linkage), 5.18 (s, 1H, OH), 
5.80 (s, 1H, CH of thiazolidinone), 7.04-8.16 (m, 11H, Ar-CH). EI-MS 
m/z: 517 (M+). Anal. Calcd. for C26H23N5O5S: C, 60.34; H, 4.48; N, 13.53. 
Found: C, 60.50; H, 4.49; N, 13.48.
1-((Dimethylamino)methyl)-3-(4-(3-(4-methoxyphenyl)-4-
oxothiazolidin-2-yl)phenyl imino)-5-nitroindolin-2-one (8)
Yield = 82%, m.p. 257–259°C. IR (KBr) cm−1: 3005 (Ar-CH), 2924 (CH2-
CH), 1718 (C=O), 1656 (C=N), 1627 (C=C), 1529 and 1350 (NO2), 1078 
(C-O-C).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.18 (s, 6H, N(CH3)2), 3.36 (s, 
2H, CH2 of thiazolidinone), 3.95 (s, 3H, OCH3), 4.19 (s, 2H, CH2 linkage), 
5.91 (s, 1H, CH of thiazolidinone), 7.32–8.05 (m, 11H, Ar-CH). EI-MS 
m/z: 531 (M+). Anal. Calcd. for C27H25N5O5S: C, 61.00; H, 4.74; N, 13.17. 
Found: C, 60.83; H, 4.76; N, 13.12.
1 - ( ( D i m e t hyl a m i n o ) m e t hyl ) - 5 - n i t ro - 3 - ( 4 - ( 4 - oxo - 3 - p -
tolylthiazolidin-2-yl)phenylimino) indolin-2-one (9)
Yield = 80%, m.p. 225–227°C. IR (KBr) cm−1: 3024 (Ar-CH), 2957 
(CH2-CH), 1729 (C=O), 1672 (C=N), 1605 (C=C), 1548 and 1313 (NO2). 
1H-NMR (CDCl3, 500 MHz) δ ppm: 2.25 (s, 6H, N(CH3)2), 2.71 (s, 3H, CH3), 
3.58 (s, 2H, CH2 of thiazolidinone), 4.04 (s, 2H, CH2 linkage), 6.17 (s, 1H, 
CH of thiazolidinone), 7.23-8.09 (m, 11H, Ar-CH). EI-MS m/z: 515 (M+). 
Anal. Calcd. for C27H25N5O4S: C, 62.90; H, 4.89; N, 13.58. Found: C, 62.71; 
H, 4.90; N, 13.63.
1-((Dimethylamino)methyl)-5-nitro-3-(4-(3-(4-nitrophenyl)-4-
oxothiazolidin-2-yl)phenyl imino)indolin-2-one (10)
Yield = 76%, m.p. 263–265°C. IR (KBr) cm−1: 3013 (Ar-CH), 2945 
(CH2-CH), 1720 (C=O), 1664 (C=N), 1626 (C=C), 1551 and 1349 (NO2). 
1H-NMR (CDCl3, 500 MHz) δ ppm: 2.27 (s, 6H, N(CH3)2), 3.61 (s, 2H, 
CH2 of thiazolidinone), 4.26 (s, 2H, CH2 linkage), 6.24 (s, 1H, CH of 
thiazolidinone), 6.93–7.95 (m, 11H, Ar-CH). EI-MS m/z: 546 (M+). Anal. 
Calcd. for C26H22N6O6S: C, 57.14; H, 4.06; N, 15.38. Found: C, 57.33; H, 
4.04; N, 15.35.
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3-(4-(3-(4-Chlorophenyl)-4-oxothiazolidin-2-yl)phenylimino)-1-
((dimethylamino)methyl)-5-nitroindolin-2-one (11)
Yield = 78%, m.p. 250–252°C. IR (KBr) cm−1: 3005 (Ar-CH), 2926 
(CH2-CH), 1732 (C=O), 1661 (C=N), 1619 (C=C), 1524 and 1337 (NO2), 
785 (C-Cl).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.18 (s, 6H, N(CH3)2), 3.32 
(s, 2H, CH2 of thiazolidinone), 4.15 (s, 2H, CH2 linkage), 6.09 (s, 1H, CH of 
thiazolidinone), 6.80–8.23 (m, 11H, Ar-CH). EI-MS m/z: 535 (M+). Anal. 




Yield = 79%, m.p. 219–222°C. IR (KBr) cm−1: 3016 (Ar-CH), 2933 (CH2-
CH), 1738 (C=O), 1659 (C=N), 1614 (C=C), 1530 and 1322 (NO2), 691 
(C-Br).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.34 (s, 6H, N(CH3)2), 3.56 (s, 
2H, CH2 of thiazolidinone), 4.20 (s, 2H, CH2 linkage), 5.82 (s, 1H, CH of 
thiazolidinone), 7.19–8.27 (m, 11H, Ar-CH). EI-MS m/z: 579 (M+). Anal. 




Yield = 76%, m.p. 286–288°C. IR (KBr) cm−1: 3381 (NH), 3023 (Ar-CH), 
2948 (CH2-CH), 1726 (C=O), 1650 (C=N), 1629 (C=C), 1535 and 1354 
(NO2).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.21 (s, 6H, N(CH3)2), 3.45 (s, 
2H, CH2 of thiazolidinone), 4.13 (s, 2H, NH2), 4.20 (s, 2H, CH2 linkage), 
5.90 (s, 1H, CH of thiazolidinone), 7.12–8.08 (m, 11H, Ar-CH). EI-MS 
m/z: 516 (M+). Anal. Calcd. for C26H24N6O4S: C, 60.45; H, 4.68; N, 16.27. 
Found: C, 60.59; H, 4.67; N, 16.21.
1-((Dimethylamino)methyl)-3-(4-(3-(2-hydroxyphenyl)-4-
oxothiazolidin-2-yl)phenyl imino)-5-nitroindolin-2-one (14)
Yield = 75%, m.p. 294–296°C. IR (KBr) cm−1: 3644 (OH), 3008 (Ar-CH), 
2952 (CH2-CH), 1719 (C=O), 1661 (C=N), 1603 (C=C), 1556 and 1347 
(NO2).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.42 (s, 6H, N(CH3)2), 3.40 (s, 
2H, CH2 of thiazolidinone), 4.15 (s, 2H, CH2 linkage), 5.36 (s, 1H, OH), 
6.13 (s, 1H, CH of thiazolidinone), 7.05-8.31 (m, 11H, Ar-CH). EI-MS 
m/z: 517 (M+). Anal. Calcd. for C26H23N5O5S: C, 60.34; H, 4.48; N, 13.53. 
Found: C, 60.22; H, 4.50; N, 13.56.
1-((Dimethylamino)methyl)-3-(4-(3-(2-methoxyphenyl)-4-
oxothiazolidin-2-yl)phenyl imino)-5-nitroindolin-2-one (15)
Yield = 77%, m.p. 239–241°C. IR (KBr) cm−1: 3012 (Ar-CH), 2930 (CH2-
CH), 1718 (C=O), 1674 (C=N), 1606 (C=C), 1525 and 1319 (NO2), 1067 
(C-O-C).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.32 (s, 6H, N(CH3)2), 3.30 (s, 
2H, CH2 of thiazolidinone), 3.82 (s, 3H, OCH3), 4.07 (s, 2H, CH2 linkage), 
6.28 (s, 1H, CH of thiazolidinone), 7.35-8.24 (m, 11H, Ar-CH). EI-MS 
m/z: 531 (M+). Anal. Calcd. for C27H25N5O5S: C, 61.00; H, 4.74; N, 13.17. 
Found: C, 61.18; H, 4.73; N, 13.13.
1 - ( ( D i m e t hyl a m i n o ) m e t hyl ) - 5 - n i t ro - 3 - ( 4 - ( 4 - oxo - 3 - o -
tolylthiazolidin-2-yl)phenylimino) indolin-2-one (16)
Yield = 74%, m.p. 283–284°C. IR (KBr) cm−1: 3024 (Ar-CH), 2946 
(CH2-CH), 1720 (C=O), 1678 (C=N), 1625 (C=C), 1542 and 1334 (NO2). 
1H-NMR (CDCl3, 500 MHz) δ ppm: 2.16 (s, 6H, N(CH3)2), 2.59 (s, 3H, 
CH3), 3.67 (s, 2H, CH2 of thiazolidinone), 4.38 (s, 2H, CH2 linkage), 5.93 
(s, 1H, CH of thiazolidinone), 6.94-8.12 (m, 11H, Ar-CH). EI-MS m/z: 515 
(M+). Anal. Calcd. for C27H25N5O4S: C, 62.90; H, 4.89; N, 13.58. Found: C, 
63.12; H, 4.87; N, 13.56.
1-((Dimethylamino)methyl)-5-nitro-3-(4-(3-(2-nitrophenyl)-4-
oxothiazolidin-2-yl)phenyl imino)indolin-2-one (17)
Yield = 79%, m.p. 202–204°C. IR (KBr) cm−1: 3017 (Ar-CH), 2959 
(CH2-CH), 1731 (C=O), 1665 (C=N), 1603 (C=C), 1537 and 1352 (NO2). 
1H-NMR (CDCl3, 500 MHz) δ ppm: 2.43 (s, 6H, N(CH3)2), 3.69 (s, 2H, 
CH2 of thiazolidinone), 4.20 (s, 2H, CH2 linkage), 5.85 (s, 1H, CH of 
thiazolidinone), 7.07–8.31 (m, 11H, Ar-CH). EI-MS m/z: 546 (M+). Anal. 




Yield = 77%, m.p. 279–280°C. IR (KBr) cm−1: 3001 (Ar-CH), 2925 (CH2-
CH), 1713 (C=O), 1657 (C=N), 1622 (C=C), 1558 and 1320 (NO2), 782 
(C-Cl).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.34 (s, 6H, N(CH3)2), 3.35 
(s, 2H, CH2 of thiazolidinone), 4.13 (s, 2H, CH2 linkage), 6.26 (s, 1H, CH of 
thiazolidinone), 7.11–8.00 (m, 11H, Ar-CH). EI-MS m/z: 535 (M+). Anal. 




Yield = 80%, m.p. 246–248°C. IR (KBr) cm−1: 3008 (Ar-CH), 2942 (CH2-
CH), 1720 (C=O), 1659 (C=N), 1617 (C=C), 1545 and 1344 (NO2), 687 
(C-Br).  1H-NMR (CDCl3, 500 MHz) δ ppm: 2.19 (s, 6H, N(CH3)2), 3.53 
(s, 2H, CH2 of thiazolidinone), 4.12 (s, 2H, CH2 linkage), 6.04 (s, 1H, CH of 
thiazolidinone), 6.86–7.75 (m, 11H, Ar-CH). EI-MS m/z: 579 (M+). Anal. 




Antitubercular potency of title compounds was estimated by agar 
dilution method (In vitro M. tuberculosis method) [34,35]. Using OADC 
growth supplement in Middlebrook 7H11 Agar, slants each test analogs 
were incorporated in 10-fold serial dilutions. M. tuberculosis H37RV 
inoculums were prepared using OADC growth supplement in fresh 
Middlebrook 7H11 Agar slants adjusted to 1 mg/ml in 0.05% tween 
80 saline diluted to 10−2 (107 CFU/ml concentration approximately). 
In 7H11 agar tubes per ml 10-fold serial dilutions of test analogs, 5 µl 
bacterial suspensions were added. At 37°C incubated the tubes and 
after 28 days, final readings were measured. Results obtained on test 
tubes (Test analog, medium and H37RV) were compared with control 
tubes (Medium and H37RV). The concentration at which complete 
inhibition of M. tuberculosis growth occurs is known as minimum 
inhibitory concentration (MIC). INH (Isoniazid) was used as standard 
drug for comparing MIC of the title analogs and the obtained results are 
depicted in Table1.
Antimicrobial activity
Agar streak dilution method was used to study antimicrobial potency of 
test analogs. Against four Gram-positive bacteria (Bacillus cereus ATCC 
11778, Micrococcus luteus ATCC 4698, Staphylococcus epidermidis ATCC 
155, and Staphylococcus aureus ATCC 9144) and three Gram-negative 
bacteria (Klebsiella pneumoniae ATCC 11298, Pseudomonas aeruginosa 
ATCC 2853, and Escherichia coli ATCC 25922) synthesized compounds 
were screened for antibacterial activity. In addition against two fungi 
(Aspergillus fumigatus ATCC 46645 and Aspergillus niger ATCC 9029) 
synthesized analogs were tested for antifungal potency. For antibacterial 
activity, at 37°C various bacterial strains were cultured in Mueller-Hinton 
broth overnight. Likewise, for antifungal activity, at 30°C, various fungal 
strains were cultured in YEPDE agar overnight. The final densities of test 
strains were made to 5 × 10−5 CFU/ml using nutrient agar medium.
MIC
Agar streak dilution method was used to find out the MIC of test 
analogs [36]. DMF was used to prepare a stock solution of test analogs. In 
specified quantity of molten sterile agar (nutrient agar for antibacterial 
activity and Sabouraud’s Dextrose Agar medium for antifungal activity) 
graded quantities of the synthesized analogs were incorporated. In 
Petri dish at 40–50°C, a specified quantity of test analogs incorporated 
medium was poured and allowed to solidify to give a 3–4 mm depth. 
Latter to the plates containing test analogs (in DMF) and medium, 
microbial suspension (5×10−5 CFU/ml) were applied. Finally, Petri 
plates were incubated at 37°C for 24 h and 48 h for bacteria and fungi, 
respectively. The lowest concentration at which no visible growth of 
bacteria or fungi is considered as MIC and the found MIC of test analogs 
and the standard drug is shown in Table 1.
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RESULTS AND DISCUSSION
Chemistry
Title compounds 5–19 were synthesized as per the protocol mentioned 
in Scheme 1. By substituting different thiazolidinone moiety at C-3 
and (dimethylamino)methyl moiety at C-1 of 5-nitroisatin, a series 
of novel Schiff and Mannich bases of 5-nitroisatin analogs 5–19 were 
synthesized in this work. A sequence of novel 1-((dimethylamino)
methyl)-3-(4-(3-(substitutedphenyl)-4-oxothiazolidin-2-yl)
phenylimino)-5-nitroindolin-2-one derivatives 5–19 were prepared 
from isatin using a multistep synthesis. Initially, isatin one was nitrated 
using nitrating mixture (sulfuric acid and nitric acid) to obtain 5-nitro 
isatin 2. In the next step 5-nitro isatin 2 was treated with p-amino 
benzaldehyde and glacial acetic acid (catalyst) in ethanol to produce 
4-(5-nitro-2-oxoindolin-3-ylideneamino)benzaldehyde 3 by Schiff base 
mechanism with the removal of one water molecule. In the succeeding 
step compound 3 underwent Mannich reaction with dimethylamine 
and formaldehyde to produce 4-(1-((dimethylamino)methyl)-5-
nitro-2-oxoindolin-3-ylideneamino)benzaldehyde 4 with loss of one 
water molecule. In the final step by treating 4-(1-((dimethylamino)
methyl)-5-nitro-2-oxoindolin-3-ylideneamino)benzaldehyde 4 with 
mercaptoacetic acid and various arylamine through cyclization reaction 
title compounds 5–19 were synthesized. Ring closure takes place with 
a loss of two water molecules. The reaction optimization, completion, 
and purity of the synthesized intermediates and final compounds are 
confirmed by TLC.
IR,  1H-NMR, mass spectra, and elemental analyses data are used to 
confirm the structures of synthesized novel 5-nitroisatin analogs 5–19. 
All spectral data are in accordance with the assigned structures. The 
presence of specific groups in compounds is represented in IR spectra 
by some characteristic absorption peaks. In IR spectrum appearance of 
a peak at 1546 and 1328 cm−1 corresponding to aromatic nitro group 
confirms the formation of 5-nitroisatin 2. Likewise, in IR spectrum 
appearance of stretching vibration for C=N at 1669 cm−1 and in NMR 
spectrum a singlet peak for aldehyde proton at δ 10.13 ppm confirms 
the assigned structure of 4-(5-nitro-2-oxoindolin-3-ylideneamino)
benzaldehyde 3. The compound 4 formed through Mannich reaction 
was confirmed by the absence of absorption bands around 3350 cm−1 
corresponds to NH stretching and appearance of a peak at 2944 cm−1 
corresponds to CH3-CH stretching in its IR spectrum. It is further 
supported by 1H-NMR spectrum in which singlet appeared at δ 4.32 ppm 
for two protons of CH2 linkage and another singlet appeared for six 
protons of dimethylamino group at δ 2.17 ppm. Title compounds show 
absorption bands in IR spectrum at 3001–3029 cm−1, 2924–2959 cm−1, 
1713–1738 cm−1, 1650–1678 cm−1, and 1603–1629 cm−1, which can be 
assignable to Ar-H, CH3-CH, C=O, C=N, and C=C vibrations, respectively. 
In addition, nitro group present in title compounds is confirmed by 
the appearance of two characteristic peaks in IR at 1524–1558 cm−1, 
and 1312–1354 cm−1. The below-mentioned conclusions were made 
after observing the 1H-NMR spectra of novel synthesized compounds 
5–19. The presence of dimethylamino moiety was evidenced by the 
appearance of singlet for six protons at δ 2.16–2.43 ppm. A singlet at 
δ 3.30–3.69 ppm for two protons is due to CH2 of thiazolidinone. The 
appearance of singlet for two protons at δ 4.04–4.38 ppm confirms 
the presence of CH2 linkage. CH of thiazolidinone was evidenced by 
appearance of one proton singlet at δ 5.80–6.28 ppm. A group of signals 
(multiplet) appeared between δ 6.80 and 8.31 ppm corresponds to Ar-H 




In vitro antitubercular activity of all title analogs was screened 
against M. tuberculosis (H37Rv strain) and MIC of entire tested analogs 
was determined and presented in Table 1 and Fig. 1. Simultaneously, 
MIC of INH was also measured to control the sensitivity of the test 
organisms. From the results, it was found that in varying degree 
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Among various tested compounds, analogs such as 6 and 13 inhibited 
the growth of M. tuberculosis at a low concentration (MIC: 3.9 µg/ml). 
Both derivatives possess amino moiety at phenyl ring attached to 
thiazolidinone ring. MIC of test compounds 7, 8, and 14 was found to 
be 7.81 µg/ml may be due to the presence of hydroxy and methoxy 
substituent in phenyl ring. In addition, derivative 15 containing 
methoxy moiety completely inhibited the growth of M. tuberculosis at 
15.62 µg/ml concentration. The MIC of analogs 5, 9, and 16 was found 
to be 31.25 µg/ml and test compounds 11, 12, and 18 were found to 
be 62.5 µg/ml. Only at higher concentration remaining synthesized 
derivatives (compounds 10, 17, and 19) displayed activity (MIC: 
≥125 µg/ml).
Antimicrobial activity
In vitro, agar streak dilution method was employed to screen the 
antimicrobial activity of test derivatives 5–19. Simultaneously, MIC 
of ciprofloxacin and ketoconazole was also measured to control the 
sensitivity of the test organisms. The MIC of standard and test analogs 
was compared effectively in Table 1 and Figs. 2-4.
Antimicrobial data indicate that test analog 6 (MIC: 1.95 µg/ml) 
exhibited superior activity than ciprofloxacin against B. cereus; whereas 
test analogs 7 and 13 (MIC: 3.9 µg/ml) exhibited similar activity and 
remaining analogs displayed inferior activity (MIC: ≥7.81 µg/ml). 
Compared to ciprofloxacin against M. luteus derivative 6 showed higher 
Scheme 1: Synthetic protocols of intermediates and title compounds (5–19)
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activity (MIC: 1.95 µg/ml) and derivatives 7 and 13 (MIC: 3.9 µg/ml) 
showed equal activity; whereas other tested derivatives showed lesser 
activity (MIC: ≥7.81 µg/ml). Against S. epidermidis test compound 6 
exhibited greater activity (MIC: 3.9 µg/ml) compared to ciprofloxacin 
and compounds 7, 8, 13, and 14 displayed identical activity (MIC: 
7.81 µg/ml); whereas leftover compounds produced subordinate activity 
(MIC: ≥15.62 µg/ml). Compound 6 (MIC: 1.95 µg/ml) exhibited similar 
activity like ciprofloxacin against S. aureus; whereas residual analog 
displayed inferior activity (MIC: ≥3.9 µg/ml). While the rest of analogs 
exhibited weaker activity (MIC: ≥7.81 µg/ml) than ciprofloxacin against 
K. pneumoniae, tested derivatives 6 and 13 showed alike activity (MIC: 
3.9 µg/ml). Against P. aeruginosa compound 6 exhibited better activity 
(MIC: 3.9 µg/ml) than ciprofloxacin and test compounds 7, 8, 13, and 
14 displayed the similar activity (MIC: 7.81 µg/ml); while rest of entire 
analogs displayed worser activity (MIC: ≥15.62 µg/ml). Compound 
6 showed alike potency (MIC: 1.95 µg/ml) as ciprofloxacin, whereas 
remaining analogs exhibited inferior activity (MIC: ≥3.9 µg/ml) than 
ciprofloxacin against E. coli. Out of 15 tested compounds, compound 
6 displayed higher activity against all tested Gram-positive and Gram-
negative bacteria than the rest of tested compounds.
Against A. fumigatus and A. niger synthesized compounds were 
screened for its antifungal activity and found to display a varying degree 
of antifungal potency. None of the tested analogs displayed superior 
or equal activity compared to Ketoconazole against both tested fungi 
(A. fumigatus and A. niger). Out of various tested analogs, compounds 
6 and 13 were found to be the most potent compounds of this series. 
From the study, in general, it was found that compounds 6–8 and 13–15 
displayed good antimicrobial activity; compounds 5, 9, and 16 exhibited 
moderate antimicrobial activity; whereas rest of title compounds 
(10–12 and 17–19) displayed poor antimicrobial activity.
Structural activity relationship
SAR of synthesized compounds is depicted in Fig. 5. In this study, overall it 
was found that title analogs 6–8 and 13–15 exhibited good antimicrobial 
activity; title analogs 5, 9, and 16 showed moderate antimicrobial activity; 
whereas all other title analogs (10–12 and 17–19) produced only reduced 
antimicrobial activity. In phenyl ring attached to thiazolidinone ring, the 
presence of electron donating substituent such as amino, hydroxy, and 
methoxy moiety might be responsible for the powerful antibacterial activity 
displayed by derivatives 6–8 and 13–15. In general, from the SAR study, it 
was found that isatin derivatives possessing electron releasing group 6–8 
and 13–15 exhibited superior antimicrobial potency than corresponding 
isatin derivatives possessing electron withdrawing moieties 9–12 and 
16–19 while unsubstituted analogs displayed intermediate activity. In 
addition, it was also found that position of the substituent does not play 
any important role in antimicrobial activity because ortho substituted 
analogs 13–19 showed almost equal activity to corresponding para 
substituted analogs 6–12. Moreover, test compounds displayed better 
activity against tested bacteria than fungi. Out of 15 title compounds, 
the potent compounds were found to be 3-(4-(3-(4-aminophenyl)-
4-oxothiazolidin-2-yl)phenylimino)-1-((dimethylamino)methyl)-5-
nitroindolin-2-one 6 and 3-(4-(3-(2-aminophenyl)-4-oxothiazolidin-2-yl)
phenylimino)-1-((dimethylamino)methyl)-5-nitroindolin-2-one 13.
CONCLUSION
In summing up, from isatin using multistep synthesis various novel Schiff 
and Mannich bases of 5-nitroisatin was synthesized by substituting 
different 3-(substitutedphenyl)-2- phenylimino thiazolidinone moiety 
at C-3 and (dimethylamino)methyl moiety at C-1 of 5-nitroisatin. FT-
















5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Isoniazid
Fig. 1: Minimum inhibitory concentration in µg/ml of synthesized 


















5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Ciprofloxacin
Fig. 2: Minimum inhibitory concentration in µg/ml of synthesized 

















5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Ciprofloxacin
Fig. 3: Minimum inhibitory concentration in µg/ml of synthesized 

















5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Ketoconazole
Fig. 4: Minimum inhibitory concentration in µg/ml of synthesized 
compounds (5–19) against various fungi
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confirm the chemical structure of all synthesized intermediate and title 
derivatives. In vitro antitubercular, antibacterial, and antifungal activities 
of all novel analogs were estimated by measuring its MIC. This series 
of analogs displayed a varying degree of antimicrobial activity (mild 
to good). SAR studies revealed that in determining the antimicrobial 
activity of novel 5-nitroisatins nature of substituent played a major 
role than the position of the substituent. Isatin derivatives possessing 
electron releasing group exhibited superior antimicrobial potency than 
corresponding isatin derivatives possessing electron withdrawing 
moieties while unsubstituted analogs displayed intermediate 
activity. Out of several 5-nitroisatins tested in this series, the potent 
antibacterial compounds were found to be 3-(4-(3-(4-aminophenyl)-
4-oxothiazolidin-2-yl)phenylimino)-1-((dimethylamino)methyl)-5-
nitroindolin-2-one 6 and 3-(4-(3-(2-aminophenyl)-4-oxothiazolidin-
2-yl)phenylimino)-1-((dimethylamino)methyl)-5-nitroindolin-2-one 
13. These derivatives displayed potent antibacterial activity which is 
greater than or almost equal to the tested reference drug. In addition, 
derivatives 6 and 13 also exhibited some notable antifungal activity 
against tested fungi. Moreover, these analogs also showed good 
antitubercular activity. For this reason, these compounds might be 
extended as a novel class of antimicrobial agents. On the other hand, to 
enhance the anti-tubercular and antibacterial activity further structural 
modification is planned.
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